New findings that RAD52 is essential for cell viability in BRCA1-, PALB2- and BRCA2- and RAD51 paralog-deficient cells, but not in normal cells, suggested that RAD52 may represent an attractive therapeutic target for killing hereditary breast cancer and ovarian cancer cells. This evidence concerns the gene BRCA1 and ovarian carcinoma.